OPEN END TURBO BULL - VERTEX PHARMACEUTICALS | Market Closed - Boerse Frankfurt Warrants 18:34:48 14/06/2024 BST | ||
| 12.96 EUR | +3.02% |
|
| Current month | +29.73% | ||
| 1 month | +69.86% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about VERTEX PHARMACEUTICALS INCORPORATED
More news
| Date | Price | Change |
|---|---|---|
| 14/06/24 | 12.96 | +3.02% |
| 13/06/24 | 12.58 | +2.36% |
| 12/06/24 | 12.29 | -3.38% |
| 11/06/24 | 12.72 | -0.63% |
| 10/06/24 | 12.8 | -1.99% |
Real-time Boerse Frankfurt Warrants
Last update June 14, 2024 at 06:34 pm
More quotesStatic data
| Product type | Knock-Out without Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | VERTEX PHARMACEUTICALS INCORPORATED |
| Issuer | 
Citi
|
| WKN | KH5CSC |
| ISIN | DE000KH5CSC1 |
| Date issued | 11/04/2023 |
| Strike | 348.5 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.2 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 13.18 € |
|---|---|
| Lowest since issue | 0.46 € |
Company Profile
Vertex Pharmaceuticals Incorporated specializes in the research, development and marketing of micromolecular drugs primarily for the treatment of cancers, viral, inflammatory and auto-immune diseases.
Net sales are distributed geographically as follows: the United States (61.2%), Europe (31.5%) and other (7.3%).
Sector
-
Ratings for Vertex Pharmaceuticals Incorporated
Trading Rating
Investor Rating
ESG Refinitiv
B+
Consensus: Vertex Pharmaceuticals Incorporated
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
480.7
USD
Average target price
463.4
USD
Spread / Average Target
-3.60%
- Stock Market
- Certificates
- Certificat